Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
06.05.2015
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 STUDY WITH APD403 IN CHEMOTHERAPY INDUCED NAUSEA & VOMITING (CINV)

Primary endpoint of preventing delayed CINV met with high significance

Cambridge, UK – 6th May 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

Dato
30.04.2015
BONESUPPORT ANNOUNCES CE-MARK OF CERAMENT™|V, THE FIRST INJECTABLE VANCOMYCIN ELUTING BONE SUBSTITUTE IN THE MANAGEMENT OF OSTEOMYELITIS
Lund, Sweden, (PRNEWSWIRE) April 29, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENT™|V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENT™|V is an extension of the company’s antibiotic eluting bone substitute portfolio which includes CERAMENT™|G, the first injectable gentamicin eluting bone substitute.  Vancomycin is used to treat gram-positive bacteria that are known to be resistant to most antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA).  The Infectious Disease Society of America recommends vancomycin as first-line therapy for these complicated infections, which include bone, and joint infections. The company is launching CERAMENT™|V immediately in all CE-mark countries.
Dato
21.04.2015
scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery
Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure.
Dato
21.04.2015
ACACIA PHARMA INITIATES PHASE 3 COMBINATION PROPHYLAXIS STUDY WITH APD421 IN POST-OPERATIVE NAUSEA & VOMITING (PONV)
Cambridge, UK – 21st April 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), the supportive care company developing  products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard antiemetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications. International consensus guidelines recommend the use of multiple anti-emetics to prevent PONV in high-risk patients.
Dato
20.04.2015
PSIOXUS THERAPEUTICS TO PRESENT PROMISING NEW DATA ON NOVEL ONCOLYTIC IMMUNONCOLOGY PLATFORM AT AACR 2015
OXFORD, UK – 16 April 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation “Antibody Armed EnAd” (AbEnAd) anti-cancer therapeutic platform at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA April 19-22, 2015. AbEnAd is the antibody armed series from the “Armed EnAd Platform” which is based upon the company’s flagship therapeutic oncolytic virus, enadenotucirev (EnAd). EnAd was developed using the principles of natural selection to specifically target and destroy cancer cells, and to allow systemic intravenous delivery.
Dato
20.04.2015
PSIOXUS THERAPEUTICS EXPANDS CLINICAL STUDIES FOR IMMUNO-ONCOLYTIC TREATMENT FOLLOWING POSITIVE RESPONSE TO INTRAVENOUS DELIVERY
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications
Dato
16.04.2015
BONESUPPORT CLOSES $14 MILLION IN FUNDING LED BY MAJOR SCANDINAVIAN PENSION FUND
Financing will be used to grow CERAMENT™ platform and expand market penetration
Dato
15.04.2015
scPharmaceuticals Elects Dorothy Coleman to Board of Directors and Appoints Brian Piekos as Chief Financial Officer
LEXINGTON, Mass., April 14, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has elected Dorothy A. Coleman to its board of directors and that it has appointed Brian Piekos as Chief Financial Officer. 
Dato
26.03.2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
SAN DIEGO and POMPEY, France, March 24, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company and Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Dato
26.03.2015
Vtesse, Inc. Forms Scientific Advisory Board

Niemann-Pick Disease experts Drs. Paul Gissen, Marc Patterson and Forbes D. Porter, along with biopharmaceutical industry leader Dr. Cristina Csimma, join Vtesse in quest to develop new treatments for people facing Niemann-Pick Disease Type C and rare diseases

GAITHERSBURG, Md., March 25, 2015 /PRNewswire/ -- Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the formation of its Scientific Advisory Board (SAB).  Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company's lead candidate, VTS-270.

Forrige Forrige 10 11 12 13 14 15 16 17 18 19 20 Næste 10 Næste